Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C181786> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- NCIT_C181786 IAO_0000115 "A chemoimmunotherapy regimen consisting of cyclophosphamide and epirubicin followed by pembrolizumab, used as a neoadjuvant or adjuvant treatment for HER-2 (EGFR2; ErbB2)-negative and hormone receptor-negative breast cancer." @default.
- NCIT_C181786 NCIT_NHC0 "C181786" @default.
- NCIT_C181786 NCIT_P106 "Therapeutic or Preventive Procedure" @default.
- NCIT_C181786 NCIT_P108 "Cyclophosphamide/Epirubicin/Pembrolizumab Regimen" @default.
- NCIT_C181786 NCIT_P208 "CL1664636" @default.
- NCIT_C181786 NCIT_R123 NCIT_C106432 @default.
- NCIT_C181786 NCIT_R123 NCIT_C124946 @default.
- NCIT_C181786 NCIT_R123 NCIT_C128037 @default.
- NCIT_C181786 NCIT_R123 NCIT_C129824 @default.
- NCIT_C181786 NCIT_R123 NCIT_C129825 @default.
- NCIT_C181786 NCIT_R123 NCIT_C141144 @default.
- NCIT_C181786 NCIT_R123 NCIT_C143250 @default.
- NCIT_C181786 NCIT_R123 NCIT_C1590 @default.
- NCIT_C181786 NCIT_R123 NCIT_C1594 @default.
- NCIT_C181786 NCIT_R123 NCIT_C163758 @default.
- NCIT_C181786 NCIT_R123 NCIT_C1748 @default.
- NCIT_C181786 NCIT_R123 NCIT_C186664 @default.
- NCIT_C181786 NCIT_R123 NCIT_C1908 @default.
- NCIT_C181786 NCIT_R123 NCIT_C1909 @default.
- NCIT_C181786 NCIT_R123 NCIT_C1968 @default.
- NCIT_C181786 NCIT_R123 NCIT_C20401 @default.
- NCIT_C181786 NCIT_R123 NCIT_C2114 @default.
- NCIT_C181786 NCIT_R123 NCIT_C2115 @default.
- NCIT_C181786 NCIT_R123 NCIT_C2161 @default.
- NCIT_C181786 NCIT_R123 NCIT_C2189 @default.
- NCIT_C181786 NCIT_R123 NCIT_C259 @default.
- NCIT_C181786 NCIT_R123 NCIT_C274 @default.
- NCIT_C181786 NCIT_R123 NCIT_C2842 @default.
- NCIT_C181786 NCIT_R123 NCIT_C307 @default.
- NCIT_C181786 NCIT_R123 NCIT_C308 @default.
- NCIT_C181786 NCIT_R123 NCIT_C405 @default.
- NCIT_C181786 NCIT_R123 NCIT_C471 @default.
- NCIT_C181786 NCIT_R123 NCIT_C474 @default.
- NCIT_C181786 NCIT_R123 NCIT_C574 @default.
- NCIT_C181786 NCIT_R123 NCIT_C697 @default.
- NCIT_C181786 normalizedInformationContent "100" @default.
- NCIT_C181786 referenceCount "1" @default.
- NCIT_C181786 hasExactSynonym "Cyclophosphamide-Epirubicin-Pembrolizumab Regimen" @default.
- NCIT_C181786 hasExactSynonym "Cyclophosphamide-Epirubicin-Pembrolizumab" @default.
- NCIT_C181786 hasExactSynonym "Cyclophosphamide/Epirubicin/Pembrolizumab Regimen" @default.
- NCIT_C181786 hasExactSynonym "Cyclophosphamide/Epirubicin/Pembrolizumab" @default.
- NCIT_C181786 hasExactSynonym "EC Followed by Pembrolizumab Regimen" @default.
- NCIT_C181786 hasExactSynonym "EC Plus Pembrolizumab Regimen" @default.
- NCIT_C181786 hasExactSynonym "EC-Pembrolizumab Regimen" @default.
- NCIT_C181786 hasExactSynonym "EC/Pembrolizumab Regimen" @default.
- NCIT_C181786 hasExactSynonym "Ellence/Cytoxan Followed by Keytruda Regimen" @default.
- NCIT_C181786 hasExactSynonym "Epirubicin/Cyclophosphamide Followed by Pembrolizumab Regimen" @default.
- NCIT_C181786 inSubset NCIT_C160950 @default.
- NCIT_C181786 inSubset NCIT_C160952 @default.
- NCIT_C181786 type Class @default.
- NCIT_C181786 isDefinedBy ncit.owl @default.
- NCIT_C181786 label "Cyclophosphamide/Epirubicin/Pembrolizumab Regimen" @default.
- NCIT_C181786 subClassOf B2663dd416e550968ff3224b93734063f @default.
- NCIT_C181786 subClassOf B8237f64719f1a38f347d327322d7c0b1 @default.
- NCIT_C181786 subClassOf B939bafe1cc15b1132228e0b70f2ab993 @default.
- NCIT_C181786 subClassOf B95342f65357c7c417e8ca2e2924d81de @default.
- NCIT_C181786 subClassOf Bec577386e8ea686cb7c3a602325915b2 @default.
- NCIT_C181786 subClassOf Bf94da76838a04bdc8928fb4bf47e72c3 @default.
- NCIT_C181786 subClassOf NCIT_C12218 @default.
- NCIT_C181786 subClassOf NCIT_C181786 @default.
- NCIT_C181786 subClassOf NCIT_C62634 @default.
- NCIT_C181786 subClassOf NCIT_C63358 @default.